文献速递胸部肿瘤

非V600 BRAF变异在NSCLC中的生物学与临床管理

Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC.
PubMed 文献 · J Thorac Oncol · 2026-01-19

本文综述非V600 BRAF变异(II/III类突变、融合、缺失、扩增)在NSCLC中的生物学、流行病学与治疗策略。BRAF突变见于约3%-8%的NSCLC,其中仅约35%为V600突变,60%-70%为非V600突变(主要在外显子11和15)。II/III类突变患者临床结局较差,目前无共识治疗策略,新兴抑制剂和联合策略正在探索中。

要点

  • NSCLC中BRAF突变约3%-8%,其中仅约35%为V600突变。
  • 非V600突变占BRAF突变NSCLC的60%-70%,主要位于外显子11和15。
  • II/III类BRAF突变患者临床结局较差,目前无共识治疗策略。

核心结论

  • 非V600 BRAF变异(II/III类突变、融合、缺失、扩增)在NSCLC中的生物学和临床意义尚未充分阐明,II/III类突变患者缺乏共识治疗策略。

研究设计与样本

  • 本文为综述,全面概述NSCLC中II/III类BRAF突变、融合、缺失和扩增的生物学、流行病学及治疗策略。

主要发现

  • BRAF突变见于约3%-8%的NSCLC患者,仅约35%的BRAF突变NSCLC肿瘤携带V600突变。
  • 其余病例中60%-70%为非V600突变,主要位于外显子11和15。
  • 与I类(V600)相比,II类和III类突变患者临床结局较差,部分因缺乏有效靶向治疗策略。
  • 双靶BRAF和MEK抑制在BRAF V600突变NSCLC中显示临床获益,但II/III类突变目前无共识治疗策略。
  • 除点突变外,BRAF融合、缺失和扩增见于初治肿瘤及其他致癌基因驱动NSCLC亚型靶向治疗获得性耐药背景,但其生物学和临床意义尚不明确。

临床怎么用

  • NSCLC分子检测应识别BRAF非V600变异(II/III类突变、融合、缺失、扩增),而非仅检测V600突变。
  • II/III类BRAF突变患者缺乏共识靶向策略,可关注新兴抑制剂和联合治疗策略的临床证据。
  • 其他致癌基因驱动NSCLC靶向治疗耐药时,应考虑BRAF变异作为耐药机制之一。

局限性

  • 非V600 BRAF变异(融合、缺失、扩增)的生物学和临床意义尚不明确。
  • II/III类BRAF突变目前无共识治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BRAF mutations are detected in approximately 3% to 8% of patients with NSCLC. In contrast to melanoma, in which most BRAF mutations occur at the V600 codon, only approximately 35% of BRAF-mutant NSCLC tumors harbor V600 mutations. Among the remaining cases, 60% to 70% present non-V600 mutations, primarily in exons 11 and 15. BRAF mutations are classified into three classes according to their kinase activity and their dependence on RAS activation. Compared with class I (V600), patients with class II and class III mutations are associated with poorer clinical outcomes partly due to the lack of effective targeted therapeutic strategies. Indeed, although dual BRAF and MEK inhibition has demonstrated clinical benefit in BRAF V600-mutant NSCLC, there is currently no consensus on treatment strategies for patients with class II and class III mutations. Beyond point mutations, other BRAF alterations (e.g., gene fusions, deletions, and amplifications) have been identified in treatment-naive tumors and in the context of acquired resistance to targeted therapies in other oncogene-driven NSCLC subtypes. However, the biology and clinical implications of these alterations remain poorly characterized. In this review, we provide a comprehensive overview on the biology, epidemiology, and therapeutic strategies of class II/III BRAF mutations, fusions, deletions, and amplifications in NSCLC. We highlight current challenges in the clinical management of BRAF-mutant NSCLC, emerging inhibitors, and combinatorial therapeutic strategies developed to treat non-V600E BRAF-driven cancers. Finally, we briefly discuss BRAF alterations in the context of resistance to targeted therapies in other oncogene-driven NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ortiz-Cuaran S, Dupriez L, Nicq C, et al. Biology and Clinical Management of Non-V600 BRAF Alterations in NSCLC. J Thorac Oncol. 2026. PMID: 41553307. doi:10.1016/j.jtho.2025.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。